ANAVEX LIFE SCIENCES CORP. — Director's Dealing 2024

Jan 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK: 0001314052
Period of Report: 2024-01-02

Reporting Person: Boenisch Sandra (PFO & Treasurer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-02	Stock Option (Right to Buy)	$10.09	A	10000	Acquired	2032-06-27	Common Stock (10000)	Direct

Footnotes

F1: On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 10,000 shares.